PuraCap Pharmaceutical LLC is rolling out two new acne products, Eptex Controlled Release Acne Wash and Eptex Controlled Release Acne Relief Lotion. Available through healthcare professionals, the products utilize a controlled release Intelli-Target™ technology that delivers treatment where it's needed most minimizing side effects.
Nestlé Skin Health has announced that Humberto Antunes, Nestlé’s CEO, will leave the company at the end of October, and will be replaced by Paul Navarre. Antunes joined Galderma, Nestlé Skin Health’s medical solutions business, in 1997, took over Galderma worldwide operations in 2004 and was named Nestlé Skin Health CEO in 2014, according to a press release.
BioPharmX announced it has begun enrollment of patients in its phase 2b clinical trial measuring the efficacy and safety of BPX-10 for treating acne vulgaris. The OPAL study is a 12-week multi-center, double-blind vehicle-controlled study of BPX-01, a fully solubilized topical minocycline gel that delivers the drug directly to the acne source while avoiding systemic exposure.
Allergan CEO and President Brent Saunders believes in a “social contract” that balances the cost of developing new medications with affordability. In a blog post on the Allergan website, Saunders noted that companies that aggressively raise prices on medications or needed items have “violated this social contract.”
Xycrobe Therapeutics announced it has entered into a research agreement with Johnson & Johnson Consumer focusing on application of Xycrobe’s technology for the treatment of inflammatory skin diseases.
BioPharmX recently announced financial results for the first quarter ending April 30 and research updates on BPX-01, a topical antibiotic for acne. The specialty pharmaceutical company focusing on dermatology and women’s health announced that it has completed full-patient enrollment in a phase 2a study of BPX-01, which will assess safety of the product in 30 patients, according to a press release.
Actress, producer and model Kate Bosworth is the new face of Allergan plc’s ACZONE® (dapsone) Gel, 7.5%. ACZONE® Gel, 7.5% is a once-a-day prescription topical treatment for acne in patients 12 years of age and older. It was approved by the U.S. Food and Drug Administration in February 2016.
AbbVie has launched a global disease education campaign on hidradenitis suppurativa called “What’s Your Sore Spot?” The campaign was begun during hidradenitis suppurativa (HS) Awareness Week, June 6-12, with the WhatsYourSoreSpot.com, which includes country-specific websites and resources about HS, according to a press release.
June is Acne Awareness Month. Recent developments reported on Healio.com/Dermatology include research finding that Epiduo Forte Gel displayed significantly greater efficacy when compared with vehicle in treating patients with moderate-to-severe acne, and that a new regimen, called CoMMPlete, effectively reduced acne among a cohort of student athletes.
DRM01 (Dermira) had positive results in a phase 2a safety and efficacy trial and, more recently, in a phase 2b study looking at dosing of the topical for patients with facial acne vulgaris.